SCHEMBL863168

SCHEMBL863168

COC(=O)c1ccc(NC(C)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
SMN1; SMN2 Q16637 5/20 0.67
ALDH1A1 P00352 4/20 0.67
LMNA P02545 2/20 0.67
MAPT P10636 3/20 0.65
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
HTT P42858 2/20 0.62
MAPK1 P28482 2/20 0.62
KDM4E B2RXH2 2/20 0.62
L3MBTL1 Q9Y468 3/20 0.61
GAA P10253 1/20 0.61
ATM Q13315 1/20 0.61
POLB P06746 1/20 0.61
HDAC1 Q13547 1/20 0.60
HPGD P15428 1/20 0.60
RECQL P46063 1/20 0.60
PKM P14618 1/20 0.58
HSD17B10 Q99714 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14563219 0.94 MEN1 (0.62) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6323372 0.94 ALDH1A1 (0.68) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6305740 0.91 SMN1; SMN2 (0.67) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL17477113 0.89 KMT2A (0.57) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL17477155 0.88 ALDH1A1 (0.72) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL10565877 0.88 KMT2A (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL19890507 0.84 KMT2A (0.57) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL28879915 0.84 MEN1 (0.67) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6263820 0.83 NPC1 (0.83) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL9551946 0.83 MAPT (0.70) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101348444-B Preparation of 2-ethoxy-4-acetaminobenzoic acid methyl ester ZHEJIANG ESIGMA ANIMAL HEALTH CO LTD 2012-01-11 CN claimed
CN-101348444-A Preparation of 2-ethoxy-4-acetaminobenzoic acid methyl ester ZHEJIANG HUINENG ANIMALS LEECH (CN) 2009-01-21 CN claimed
US-4397763-A TITANIUM-BASED PHILLIPS PETROLEUM COMPANY (US) 1983-08-09 US claimed
US-4330648-A MIXTURE OF TITANIUM HALIDE, MAGNESIUM OR MANGANOUS CHLORIDE DIHYDROCARBYLALUMINUM HALIDE OR HYDRIDE AND AN ETHER-ALCOHOL PHILLIPS PETROLEUM COMPANY (US) 1982-05-18 US claimed
US-4312784-A TITANIUM HALIDE, LEWIS BASE, MAGNESIUM OR MANGANOUS CHLORIDE, UNSATURATED HYDROCARBON AND TRIHYDROCARBYLALUMNIUM PHILLIPS PETROLEUM CO. (US) 1982-01-26 US claimed
US-4242480-A TWO OR THREE COMPONENT SYSTEM COMPRISING A TITANIUM HALIDE, LEWIS BASE, MAGNESIUM OR MANGANESE CHLORIDE, UNSATURATED HYDROCARBON, ORGANOALUMINUM COMPOUND PHILLIPS PETROLEUM COMPANY (US) 1980-12-30 US claimed
EP-0002521-A1 Titanium-magnesium/manganese-aluminum catalyst and process for olefin polymerization PHILLIPS PETROLEUM COMPANY (US) 1979-06-27 EP claimed
EP-0002522-A1 Process for polymerizing butene-1 PHILLIPS PETROLEUM COMPANY (US) 1979-06-27 EP claimed
US-20250154115-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-05-15 US disclosed
WO-2025098450-A1 PRMT5 INHIBITOR AND PREPARATION METHOD THEREFOR 北京泰德制药股份有限公司 2025-05-15 WO disclosed
EP-4472954-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF The University of North Carolina at Chapel Hill (US) 2024-12-11 EP disclosed
CN-115536605-B Preparation method and application of polysubstituted oxazole compound with participation of boron reagent 广东工业大学 2023-12-15 CN disclosed
WO-2023154466-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-08-17 WO disclosed
WO-2023154466-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-08-17 WO disclosed
EP-0454330-A1 Benzimidazolinone derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-10-30 EP disclosed
US-4397763-A TITANIUM-BASED PHILLIPS PETROLEUM COMPANY (US) 1983-08-09 US disclosed
US-4330648-A MIXTURE OF TITANIUM HALIDE, MAGNESIUM OR MANGANOUS CHLORIDE DIHYDROCARBYLALUMINUM HALIDE OR HYDRIDE AND AN ETHER-ALCOHOL PHILLIPS PETROLEUM COMPANY (US) 1982-05-18 US disclosed
US-4312784-A TITANIUM HALIDE, LEWIS BASE, MAGNESIUM OR MANGANOUS CHLORIDE, UNSATURATED HYDROCARBON AND TRIHYDROCARBYLALUMNIUM PHILLIPS PETROLEUM CO. (US) 1982-01-26 US disclosed
US-4242480-A TWO OR THREE COMPONENT SYSTEM COMPRISING A TITANIUM HALIDE, LEWIS BASE, MAGNESIUM OR MANGANESE CHLORIDE, UNSATURATED HYDROCARBON, ORGANOALUMINUM COMPOUND PHILLIPS PETROLEUM COMPANY (US) 1980-12-30 US disclosed
EP-0002521-A1 Titanium-magnesium/manganese-aluminum catalyst and process for olefin polymerization PHILLIPS PETROLEUM COMPANY (US) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154115-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF PFKL, IP6K2, IP6K1 MEN1 4434/4885KMT2A 1686/4885SMN1; SMN2 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.